Podcasts

E-Books

Videos

Articles

Clinical

Tony Hagen is senior managing editor for The Center for Biosimilars

A rituximab biosimilar developed by Celltrion Healthcare demonstrates safety and efficacy in patients with relapsed or refractory aggressive B-cell lymphoma, in findings presented at EHA25 Virtual, the annual meeting of the European Hematology Association.
 

Celltrion Biosimilar Shows Efficacy in DLBCL Combination

Investigators reported an 88% overall response rate for a Sandoz rituximab biosimilar in combination with chemotherapy in patients with CD20-positive diffuse large B-cell lymphoma.

Sandoz R-CHOP Combination Confirms Findings in REFLECT

The FDA has approved Pfizer’s pegfilgrastim biosimilar Nyvepria for use in lowering the incidence of infection as manifested by febrile neutropenia.

FDA Approves Pfizer Pegfilgrastim Biosimilar Nyvepria

Investigators produced what they described as the first evidence supporting the use of biosimilar erythropoiesis-stimulating agents (ESAs) in patients with myelofibrosis-related anemia.

Biosimilar ESA Is Effective in Myelofibrosis Anemia

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Canada Health has approved the launch of Sandoz' pegfilgrastim and rituximab biosimilars.
 

Sandoz Gets Canada's Nod to Launch Ziextenzo, Riximyo

Isha Bangia, PharmD, MBA, is a manager of US market access at Certara Evidence & Access. She received her PharmD from Rutgers University and an MBA from Johns Hopkins University. Her current responsibilities include optimizing product value stories and working with customers to improve access across the US healthcare system. Her experience includes practicing pharmacy, payer market research, and pharma strategy and analytics. Her work has covered many therapeutic areas, including biosimilars, oncology, diabetes, vaccines, and rare diseases.

Biosimilar discounts to reference products have improved over time, but they are deeper in some categories than others.
 

Biosimilar Discounts Vary by Category 

As part of pilot program designed to improve access to cheaper medications in oncology, a rituximab biosimilar from Celltrion has been approved for use by the World Health Organization (WHO).

WHO Clears Celltrion Rituximab for Use

Recognizing that oncology practices are struggling with the pandemic, the Center for Medicare and Medicaid Innovation has eased some performance requirements.
 

Timeline Is Extended for Practices Struggling With COVID-19

Here is a summary of our coverage from ASCO20 Virtual, the annual meeting for the American Society of Clinical Oncology (ASCO).

ASCO20 Virtual Biosimilars Roundup

Clinical trials leading up to biosimilar approval may not reveal the full safety and efficacy profile of biosimilars vs reference products, and postmarketing studies may be essential to elucidate any differences, investigators said.

Oncology